Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Humanwell Healthcare (Group) Co's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 52.83%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
SHSE:600079's 3-Year ROIIC % is ranked better than 84.46% of 946
companies
in the Drug Manufacturers industry
Industry Median: 3.635
vs SHSE:600079: 52.83
Humanwell Healthcare (Group) Co (SHSE:600079) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Humanwell Healthcare (Group) Co 3-Year ROIIC % Related Terms
Humanwell Healthcare (Group) Co 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Humanwell Healthcare (Group) Co 3-Year ROIIC % Chart
SHSE:600079 vs ZTS, UTHR: 3-Year ROIIC % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Humanwell Healthcare (Group) Co's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Humanwell Healthcare (Group) Co 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Humanwell Healthcare (Group) Co's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Humanwell Healthcare (Group) Co's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Humanwell Healthcare (Group) Co (SHSE:600079) has a 3-Year ROIIC % of 52.83 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Humanwell Healthcare (Group) Co and its competitors. This is 1621% above median its historical median of 3.07. According to the industry distribution chart, Humanwell Healthcare (Group) Co ranks #147 out of 946 companies in the Drug Manufacturers industry, placing it in the top 15.5%.
Is Humanwell Healthcare (Group) Co's 3-Year ROIIC % too high?
Humanwell Healthcare (Group) Co's current 3-Year ROIIC % of 52.83 is 1621% above median its 10-year median of 3.07. The Drug Manufacturers industry median 3-Year ROIIC % is 3.64. Humanwell Healthcare (Group) Co's value of 52.83 is 1353.4% above this industry median. Based on the distribution chart, Humanwell Healthcare (Group) Co ranks #147 out of 946 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Humanwell Healthcare (Group) Co has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Humanwell Healthcare (Group) Co's 3-Year ROIIC % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Humanwell Healthcare (Group) Co ranks #147 out of 946 companies for 3-Year ROIIC %. This places Humanwell Healthcare (Group) Co in the top 16% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 3.64. Humanwell Healthcare (Group) Co's value of 52.83 is 1353.4% above this benchmark. While the company's 10-year median is 3.07 vs. the industry median of 3.64, Humanwell Healthcare (Group) Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.64, based on 946 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Humanwell Healthcare (Group) Co's current 3-Year ROIIC % of 52.83 is 1353.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Humanwell Healthcare (Group) Co and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Humanwell Healthcare (Group) Co's current 3-Year ROIIC % is 52.83, which is 1621% above median its own 10-year median of 3.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Humanwell Healthcare (Group) Co stock overvalued right now?
Based on GuruFocus' analysis, Humanwell Healthcare (Group) Co (SHSE:600079) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥21.74, compared to a current price of ¥17.56 — trading 19.2% below its estimated fair value. The current 3-Year ROIIC % is 52.83, which is 1621% above median its 10-year median of 3.07 and 1353.4% above the Drug Manufacturers industry median of 3.64. Humanwell Healthcare (Group) Co's overall GF Score™ is 58/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Humanwell Healthcare (Group) Co (SHSE:600079), the current 3-Year ROIIC % is 52.83 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Humanwell Healthcare (Group) Co (SHSE:600079) Overvalued in 2026?
Based on GuruFocus' analysis, Humanwell Healthcare (Group) Co stock appears to be undervalued.
The current stock price of ¥17.56 is trading 19.2% below its estimated GF Value™ of ¥21.74.
GuruFocus considers Humanwell Healthcare (Group) Co to be Modestly Undervalued.
Key valuation signals for SHSE:600079:
3-Year ROIIC %: 52.83 (1621% above median its 10-year median of 3.07)
GF Value™: ¥21.74 vs. price of ¥17.56 (19.2% below fair value)
Industry Position: 1353.4% above the Drug Manufacturers median (#147 of 946)
No single metric tells the full story. See the SHSE:600079 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Humanwell Healthcare (Group) Co Business Description
Humanwell Healthcare (Group) Co Ltd is a China-based integrated healthcare solution provider. It provides medicinal products including fertility-regulating drugs, Uyghur medicine, traditional Chinese medicine, medical devices, over-the-counter medicines, anti-infection drugs, herbal medicines, and biological products. The organization has a business presence in China and other international countries.
58GF Score
Get the complete analysis for SHSE:600079
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600079 has been successfully added to your 
